TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Sana Biotechnology
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Sana Biotechnology published research in Nature Biotechnology demonstrating successful in vivo gene editing of human hematopoietic stem cells using fusogen technology, potentially transforming treatment for diseases like sickle cell and beta thalassemia without conditioning chemotherapy.

Insights
JPMpK   neutral

Mentioned as a previous employer of Zastre & Co's founding team, with no direct positive or negative implications


SANA   positive

Published breakthrough research in a top-tier journal, demonstrated novel gene editing technology with potential transformative medical applications, and outlined clear development pathway for future treatments